NasdaqGM:RAPPPharmaceuticals
How RAP-219 Phase 2a Data and 2026 Phase 3 Plans At Rapport Therapeutics (RAPP) Has Changed Its Investment Story
Rapport Therapeutics recently reported new data and post hoc analyses from its Phase 2a trial of RAP-219 in drug-resistant focal onset seizures, presented at the 2025 American Epilepsy Society Meeting, highlighting statistically significant improvements in several seizure-related patient-reported outcomes and confirming target engagement in key brain regions.
The company also outlined plans for an end-of-Phase 2 meeting with the FDA and the potential launch of two pivotal Phase 3 trials in...